Breakthrough medicines to improve gastrointestinal function
Motus is a biopharmaceutical company developing peptide therapeutics for the treatment of gastrointestinal (GI) diseases. Motus’ lead product candidate, relamorelin, is a potent, best-in-class, Phase 2 ghrelin agonist for the treatment of diabetic gastroparesis, a GI complication of diabetes and other GI functional disorders for which there are currently limited therapeutic options.
Motus spun out of Rhythm Health in 2016 and was acquired by Allergan later the same year.
Year Invested: 2010
Location: Boston, Mass.